Three steps forward in efficient myeloid biomarker learning

Published on 06/11/2021

3 min read

More than six people die every hour in the US from a blood cancer. Solutions can’t come fast enough for those who suffer with these cancers all around the world.

More than six people die every hour in the US from a blood cancer. Solutions can’t come fast enough for those who suffer with these cancers all around the world. Fortunately, researchers studying blood diseases have experienced rapid advances in their capabilities to develop and test effective therapies with some extremely significant advancements.

1. Next-generation sequencing (NGS) 

Some of the most difficult limitations of molecular profiling for hematological cancer disorders include accurate detection of mutations in GC-rich gene regions and insertions or deletions in challenging genes. Data analysis on NGS DNA samples identifies complex variants to accurately identify myeloid malignancies. This validation of targeted mutations has encouraged many medical centers to order NGS testing for every acute myeloid leukemia case.

Faster, more efficient NGS analysis can drive better hematological cancer research outcomes to potentially improve care for patients with blood cancers and diagnosis of new cases.

 2. Guideline evolution 

International guidelines for hematological cancer diagnosis and treatment are continuously evolving and create the need for laboratories’ fast adaptation. Those evidence-based guidelines by physician commissions contribute to improving the clinical standard of care. The World Health Organization, European Hematology Association, European LeukemiaNet, College of American Pathologists and the American Society of Hematology call for increased use of NGS testing for initial diagnostic workup of blood cancers.

Detection of the relevant biomarkers for myeloid malignancies by NGS, per international guidelines, helps to ensure optimal clinical trial enrollment, therapy validation, dose protocols and other research benefits. A solution that can be constantly updated and inform based on those guidelines ensures that the research is always current.

3. Global application 

The accurate assessment of biomarkers and the validity of resulting research findings depend on reliable DNA and RNA fusion panels and easily reproducible results. Data analysis and reporting in a comprehensive platform eliminates silos of valuable data and maximizes its application.

The SOPHiA DDM™ platform enables the upload of multimodal data from any environment to one of the world’s largest networks of connected labs. Data remains the property of the healthcare institution, but pseudonymized and pooled with like data, it can propel research and ultimately treatment forward with the goal of improved patient care.

Learn more about the capabilities of SOPHiA DDM™ platform for myeloid biomarker detection and more by contacting us today.

Sign Up To Our Newsletter

Enter your email address to join our mailing list and receive the latest news and updates from SOPHiA GENETICS. You can unsubscribe by using the link integrated with the communication at any time. By clicking to “sign up”, you agree that SOPHiA GENETICS will process your data in accordance with its Privacy Policy

pink dots icon

Related Posts

pink dots icon

Want to know more?
Get in touch with us.

Our client services team is on hand to help.